文献速递头颈外科

四联方案——某三级医院对头颈癌姑息性放疗方案的应用经验

Quad Shot-A Tertiary Hospital Experience With a Palliative Radiotherapy Regimen for Head and Neck Cancer.
PubMed 文献 · Head Neck · 2025-06-02

回顾性分析2017至2024年在美因茨大学医学中心接受四联方案(QS)治疗的51例头颈部鳞状细胞癌患者,评估缓解、生存和毒性。中位总生存期为5.9个月(95%CI:4.3-10.5),39例可评估患者中16例客观缓解、21例疾病稳定,仅观察到2例3级及以上毒性且很可能归因于其他原因。作者认为QS耐受良好并在多数患者中显示出有意义的缓解。

要点

  • 51例头颈部鳞癌患者接受四联方案(QS)姑息性放疗,中位总生存期5.9个月(95%CI:4.3-10.5)。
  • 39例可评估患者中16例客观缓解、21例疾病稳定。
  • 仅2例出现3级及以上毒性,且很可能归因于其他原因。

核心结论

  • 作者认为四联方案(QS)耐受良好,并在多数患者中显示出有意义的缓解。
  • 基于高度姑息性患者队列的真实世界数据,作者讨论了QS处方的若干考量。

研究设计与样本

  • 回顾性评估2017年至2024年在美因茨大学医学中心接受四联方案(QS)治疗的51例头颈部鳞状细胞癌患者的缓解、生存和毒性。

主要发现

  • 中位总生存期为5.9个月(95%CI:4.3-10.5)。
  • 39例患者可评估缓解,其中16例客观缓解,21例疾病稳定。
  • 仅观察到2例3级及以上毒性,且很可能归因于其他原因。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Head and neck cancer patients often present with locally advanced disease. For some patients, palliative treatment schedules focused on symptom control are often preferred. Perhaps the most widely used of these is the so-called Quad Shot (QS) regimen. METHODS: We evaluated 51 patients with head and neck squamous cell carcinomas treated with QS at University Medical Centre Mainz between 2017 and 2024 for response, survival, and toxicity. RESULTS: Median overall survival was 5.9 (95% CI: 4.3-10.5) months. Thirty-nine patients could be evaluated for response; out of these, 16 patients had an objective response, and 21 patients had stable disease. Only two cases of toxicity Grade 3 or higher were observed and are most likely attributable to other reasons. CONCLUSION: QS was well tolerated and showed a meaningful response in most patients. Using real-world data from a highly palliative patient cohort, we discuss several considerations for QS prescription.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Nikolaidou E, Bostel T, Mayer A, et al. Quad Shot-A Tertiary Hospital Experience With a Palliative Radiotherapy Regimen for Head and Neck Cancer. Head Neck. 2025. PMID: 40457636. doi:10.1002/hed.28202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。